SB 030

Drug Profile

SB 030

Alternative Names: SB-030; SBCV 030

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator SYMIC Biomedical
  • Class Proteoglycans; Vascular disorder therapies
  • Mechanism of Action Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Peripheral arterial disorders

Most Recent Events

  • 24 Feb 2017 Symic Biomedical completes enrolment in its phase I/II trial for Peripheral arterial disorders in Australia and New Zealand (Parenteral)
  • 27 Oct 2015 Phase-I/II clinical trials in Peripheral arterial disorders in Australia and New Zealand (Parenteral)
  • 26 Aug 2015 Symic Biomedical receives phase II SBIR grant from the National Institutes of Health for SB 030 development in Arteriovenous fistula
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top